Clinical Trials Directory

Trials / Completed

CompletedNCT03174002

Handling Oxygenation Targets in the Intensive Care Unit

Handling Oxygenation Targets in Adults With Acute Hypoxaemic Respiratory Failure in the Intensive Care Unit: A Randomised Clinical Trial of a Lower Versus a Higher Oxygenation Target

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
2,928 (actual)
Sponsor
Aalborg University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Handling oxygenation targets (HOT) is standard of care in the intensive care unit (ICU), however the quality and quantity of evidence is low and potential harm has been reported. The aim of the HOT-ICU trial is to assess the overall benefits and harms of two levels of oxygenation targets in adult critically ill patients with acute hypoxaemic respiratory failure in the ICU.

Detailed description

Acutely ill adults with hypoxaemic respiratory failure admitted to the intensive care unit (ICU) are at risk of life-threatening hypoxia, and thus oxygen is administered. However, the evidence on the optimal level of oxygenation is of low quantity and quality with no firm evidence for benefit or harm. Importantly, liberal use of supplementary oxygen may increase the number of serious adverse events including death. The aim of the HOT-ICU trial is to assess the benefits and harms of two targets of partial pressure of oxygen in arterial blood (PaO2) in guiding the oxygen administration in acutely ill adults with hypoxaemic respiratory failure at ICU admission.

Conditions

Interventions

TypeNameDescription
DRUGOxygenOxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
DRUGOxygenOxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge

Timeline

Start date
2017-06-19
Primary completion
2020-11-03
Completion
2021-08-03
First posted
2017-06-02
Last updated
2021-10-26

Locations

37 sites across 7 countries: Denmark, Finland, Iceland, Netherlands, Norway, Switzerland, United Kingdom

Source: ClinicalTrials.gov record NCT03174002. Inclusion in this directory is not an endorsement.